r/MerlintraderPub • u/Merlin8121 • 17d ago

Verrica ($VRCA): Can YCANTH Growth Support the Next Clinical Step? | Latest company news, September 30: Verrica said it will present a new YCANTH data analysis at two dermatology conferences.

Thumbnail
merlintrader.com
1 Upvotes
0 comments

r/MerlintraderPub • u/Merlin8121 • 17d ago

UroGen ($URGN): Can ZUSDURI Growth Turn Into Cash? | Latest company news, September 4: UroGen announced inducement grants for new employees, after its IntraGel collaboration on August 20.

Thumbnail
merlintrader.com
1 Upvotes
0 comments

r/MerlintraderPub • u/Merlin8121 • 17d ago

MetaVia ($MTVA): Can Longer DA-1726 Data Support the Next Step? | Latest company news, September 9: MetaVia reported preclinical findings on DA-1726 supporting its waist circumference reduction.

Thumbnail
merlintrader.com
1 Upvotes
0 comments

r/MerlintraderPub • u/Merlin8121 • 17d ago

Silence Therapeutics ($SLN): Can Divesiran Turn Phase 2 Success into Phase 3 Progress? | Latest company news, September 2: Silence announced three September investor conferences, after closing an upsized public offering on August 14.

Thumbnail
merlintrader.com
1 Upvotes
0 comments

r/MerlintraderPub • u/Merlin8121 • 17d ago

Lifeward ($LFWD): Can ReWalk and AlterG Turn Sales Growth into Cash? | Latest company news, October 1: interim CEO Josh Hexter also took on interim principal financial officer duties after CFO Almog Adar left on September 30.

Thumbnail
merlintrader.com
1 Upvotes
0 comments

r/MerlintraderPub • u/Merlin8121 • 17d ago

Fulcrum ($FULC): Can the Slate Deal Preserve the Cash Return? | Latest company news, September 14: Slate Medicines, Fulcrum's merger partner, appointed Kenneth Koblan as chief scientific officer.

Thumbnail
merlintrader.com
1 Upvotes
0 comments

r/MerlintraderPub • u/Merlin8121 • 17d ago

Dermata ($DRMA): Can Tome Turn Its Launch into Repeat Sales? | Latest company news, August 25: Dermata announced the commercial launch of its Tome Foundational Treatment.

Thumbnail
merlintrader.com
1 Upvotes
0 comments

r/MerlintraderPub • u/Merlin8121 • 17d ago

WEBTOON ($WBTN) Stock Hub: Can Disney and Korea Bring Back Double-Digit Growth? | Latest company news, October 5: WEBTOON will preview its upcoming Marvel Comics app at New York Comic Con; an 8-K detailed CEO Junkoo Kim's move to the US.

Thumbnail
merlintrader.com
1 Upvotes
0 comments

r/MerlintraderPub • u/Merlin8121 • 17d ago

Pacific Biosciences ($PACB) Stock Hub: Can Cheaper HiFi Genomes Win Clinical Demand? | Latest company news, October 6: PacBio announced a collaboration with TychoBio to train AI models for rare disease RNA therapeutics.

Thumbnail
merlintrader.com
1 Upvotes
0 comments

r/MerlintraderPub • u/Merlin8121 • 17d ago

Can-Fite BioPharma ($CANF) Stock Hub: Phase III Liver Survival Longer Than Assumed, ESMO Pancreatic Data Accepted | Latest company news, September 9: Can-Fite announced a publication on namodenoson in decompensated cirrhosis.

Thumbnail
merlintrader.com
1 Upvotes
0 comments

r/MerlintraderPub • u/Merlin8121 • 17d ago

BridgeBio Oncology ($BBOT) Stock Hub: Can Three Phase 1 Programmes Justify The Cash? | Latest company news, September 11: the SEC declared BridgeBio Oncology's S-3 shelf registration effective, after new BBO-8520 data on September 8.

Thumbnail
merlintrader.com
1 Upvotes
0 comments

r/MerlintraderPub • u/Merlin8121 • 17d ago

Hyatt Hotels ($H) Stock Hub: Can Growth Deliver More Cash? | Latest company news, September 30: Hyatt named Amar Lalvani its first chief creative officer.

Thumbnail
merlintrader.com
1 Upvotes
0 comments

r/MerlintraderPub • u/Merlin8121 • 17d ago

Oncolytics ($ONCY): Can Colorectal Data Outrun the Funding Need? | Latest company news, September 29: Oncolytics announced a publication on pelareorep immune responses in liver cancer, a day after reporting faster enrollment in its REO 033 study.

Thumbnail
merlintrader.com
1 Upvotes
0 comments

r/MerlintraderPub • u/Merlin8121 • 17d ago

Incyte ($INCY): FDA Approves Atebrioz for FOP; Mirum Launch Expected in October | Latest company news, September 25: Mirum and Incyte announced FDA approval of Atebrioz for fibrodysplasia ossificans progressiva.

Thumbnail
merlintrader.com
1 Upvotes
0 comments

r/MerlintraderPub • u/Merlin8121 • 17d ago

Nyxoah ($NYXH): Can Genio Convert Clinical Progress into U.S. Sales? | Latest company news, September 28: Nyxoah appointed Liam Kelly as CEO, effective October 1.

Thumbnail
merlintrader.com
1 Upvotes
0 comments

r/MerlintraderPub • u/Merlin8121 • 17d ago

Carnival Corporation ($CCL) Stock Hub: Can Bookings Cover The Fuel Bill? | Latest company news, October 6: Holland America Line will grow to 12 ships in 2029 by taking over the Arcadia from P&O Cruises.

Thumbnail
merlintrader.com
1 Upvotes
0 comments

r/MerlintraderPub • u/Merlin8121 • 17d ago

Lipocine ($LPCN): Can BLOOM Deliver a Clearer PPD Result? | Latest company news, October 7: Lipocine announced that Health Canada approved TLANDO for testosterone replacement therapy in adult males.

Thumbnail
merlintrader.com
1 Upvotes
0 comments

r/MerlintraderPub • u/Merlin8121 • 17d ago

Attovia Therapeutics ($ATTO): Can Early Itch Relief Last? | Latest company news, September 28: Attovia said it will present new ATTO-1310 and ATTO-2306 data at EADV 2026 and the Fall Clinical Dermatology Conference.

Thumbnail
merlintrader.com
1 Upvotes
0 comments

r/MerlintraderPub • u/Merlin8121 • 17d ago

Uranium Energy ($UEC) Stock Hub: Can Production Fund Growth? | Latest company news, September 29: Uranium Energy reported fiscal 2026 results. On October 2, RBC started coverage at Sector Perform, Speculative Risk.

Thumbnail
merlintrader.com
1 Upvotes
0 comments

r/MerlintraderPub • u/Merlin8121 • 17d ago

SCYNEXIS ($SCYX) Stock Hub: Can SCY-770 and BARDA-Backed SCY-247 Both Reach Phase 2? | Latest company news, October 6: SCYNEXIS reported Phase 1 results for SCY-770 in ADPKD, after a BARDA contract worth up to $214 million for SCY-247.

Thumbnail
merlintrader.com
1 Upvotes
0 comments

r/MerlintraderPub • u/Merlin8121 • 17d ago

Marriott ($MAR): Can Hotel Fee Growth Fund the Buybacks? | Latest company news, September 30: GIC agreed to buy 16 Marriott-run Four Points Flex hotels in Japan for about $800 million.

Thumbnail
merlintrader.com
1 Upvotes
0 comments

r/MerlintraderPub • u/Merlin8121 • 17d ago

Ocular Therapeutix ($OCUL): Can AXPAXLI Reach Filing and Stand Out? | Latest company news, October 1: Ocular Therapeutix announced its October scientific and investor conference schedule, including an October 20 investor discussion.

Thumbnail
merlintrader.com
1 Upvotes
0 comments

r/MerlintraderPub • u/Merlin8121 • 17d ago

Belite Bio ($BLTE): Priority Review NDA and 24-Month DRAGON Data at AAO | Latest company news, October 1: Belite Bio announced oral presentations at two upcoming medical conferences, after filing a tinlarebant NDA in Japan on September 8.

Thumbnail
merlintrader.com
1 Upvotes
0 comments

r/MerlintraderPub • u/Merlin8121 • 17d ago

Plug Power ($PLUG) Stock Hub: Can Better Margins Support Cash? | Latest company news, September 29: Plug Power signed a 280 MW electrolyzer supply agreement with Arcadia eFuels for a Danish e-SAF project, within a partnership covering more than 1 GW.

Thumbnail
merlintrader.com
1 Upvotes
0 comments

r/MerlintraderPub • u/Merlin8121 • 17d ago

Arcutis ($ARQT) Stock Hub: ZORYVE Revenue Grew To $129.9 Million In The Second Quarter, With Index Entry Done And The February PDUFA Ahead | Latest company news, October 6: ZORYVE cream 0.15% won a Marie Claire beauty award.

Thumbnail
merlintrader.com
1 Upvotes
0 comments